Telaprevir for previously untreated chronic hepatitis C virus infection.

By I. Jacobson, J. Mchutchison, G. Dusheiko, Adrian M. Di Bisceglie, K. Reddy, N. Bzowej, P. Marcellin, A. Muir, P. Ferenci, R. Flisiak and 14 more. New England Journal of Medicine, 2011

2,552 citations recorded by the source corpus.

Subfields: Genetics, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/8b6d07df0c160ac4023211d31bd3cc31b4db5bd9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. James O. Lloyd-Smith
2. Claude Loverdo

In Hepatology

1. Christoph Sarrazin
2. A. Aghemo
3. G. Dusheiko
4. M. Puoti
5. X. Forns
6. J. Pawlotsky

In Infectious Diseases

1. James O. Lloyd-Smith
2. Nicholas C. Wu

Citations in the corpus

• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014, neutral): “Hispanic 26 (12) 20 (9) 29 (13) 26 (12)”
• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, background): “In the Phase III trials of boceprevir and telaprevir in HCV genotype 1 treatment-naïve patients, triple therapy regimens achieved higher SVR rates than PegIFN-a and ribavirin dual therapy, of the order of 65% to 75% [7] [8] [9] [10].”
• A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity (2014, background): “In 2011, the first two protease inhibitors were approved and used in combination with standard treatment [6,7].”
• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, background): “In the phase III trials of boceprevir and telaprevir in HCV genotype 1 treatment-naïve patients, triple therapy regimens achieved higher SVR rates than pegylated IFN-α/ribavirin dual therapy, of the order of 65% to 75% [4-7].”
• Telaprevir for retreatment of HCV infection. (2011, neutral): “Any adverse event 39 (15) 29 (11) 4 (3)”
• Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection (2011, neutral): “Rash events of any severity† 40 (7) 14 (9) 10 (6) 9 (8) 7 (7)”
• EASL Recommendations on Treatment of Hepatitis C 2016. (2017, background): “In the phase III trials of boceprevir and telaprevir in HCV genotype 1 treatment-naïve patients, triple therapy regimens achieved higher SVR rates than pegylated IFN-α/ribavirin dual therapy, of the order of 65% to 75% [4-7].”